H. Lundbeck A/S (Lundbeck) announced positive results, meeting its primary endpoint, in the multiple IV dosing part of PROCEED, an adaptive phase IIb dose-finding and route of administration trial of bocunebart (Lu AG09222). The trial investigated bocunebart as a potential treatment for the prevention of migraine in a population that experienced 1-4 previous preventive treatment failures in the past 10 years (NCT06323928). This mechanism operates through a pathway distinct from that targeted by anti-calcitonin gene-related peptide (anti-CGRP) therapies.
Bocunebart represents a potential new treatment class and could provide an alternative option for migraine prevention, offering hope to individuals severely affected by the condition. Bocunebart is an investigational compound, not approved by the US Food and Drug Administration (FDA) or any other regulatory agency, and the efficacy and safety of bocunebart have not been established.
